An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States
Lupus Feb 09, 2022
Organ damage develops in nearly 33%–50% of patients with systemic lupus erythematosus (SLE) within 5 years of diagnosis. Researchers herein examined SLE patients in the USA to estimate the healthcare resource utilization (HCRU) and costs linked with the development of organ damage in these patients.
Using the PharMetrics Plus administrative claims database, researchers conducted a retrospective study (GSK study 208380) of 360,803 patients with a diagnosis of SLE; these comprised 8,952 patients meeting the inclusion criteria for the presence of new organ damage [mean (standard deviation (SD)) age: 46.4 (12.2) years; 92% females].
Organ damage most commonly involved following sites: neuropsychiatric (22.0%), ocular (12.9%), and cardiovascular (11.4%).
Disease severity and proportion of moderate/severe flare episodes significantly increased from pre- to post-index date.
Overall, similar SLE-related medication patterns were observed pre- vs post-index date.
From pre- to post-index date, there was an increase in inpatient, emergency department and outpatient claims; 71% higher mean (SD) all-cause costs were recorded post- vs pre-index date ($26,998 [57,982] vs $15,746 [29,637], respectively).
Overall findings suggest a profound economic impact of organ damage in patients with SLE and support lowering or preventing organ damage for reducing the burden for patients and healthcare providers.
Exclusive Write-ups & Webinars by KOLs
Daily Quiz by specialty
Paid Market Research Surveys
Case discussions, News & Journals' summaries